

Effects of Sokatin® on emotional memory and set shifting

Submission date 25/02/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 14/04/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 01/09/2011	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Francesca Regen

Contact details
Eschenallee 3
Berlin
Germany
14050

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
750402.01.020

Study information

Scientific Title

A phase I study to assess the effects of repeated oral doses of Sokatin® (WS® 1261) for 2 weeks on emotional memory and set shifting in healthy volunteers

Study objectives

The objective of this clinical trial is to describe the influence of a two weeks treatment with Sokatin® (WS® 1261) on emotional memory and set shifting as well as working memory measured with functional magnetic resonance imaging and with a battery of psychometric test scales in healthy volunteers.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethik Kommission des Landes Berlin approved on the 8th December 2009 (ref: ZS EK 15 533/09)

Study design

Single centre double-blind randomised placebo-controlled cross-over trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Emotional memory and set shifting

Interventions

1 tablet containing 500 mg Sokatin® or placebo taken in the morning.

Schedule:

Screening phase: up to 14 days

Treatment period 1: verum or placebo for 14 days once daily

Wash-out period: 14 days

Treatment period 2: placebo or verum for 14 days once daily

Total duration after baseline: day 1 to day 43

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Sokatin® (WS® 1261)

Primary outcome measure

Memory tasks and set shifting measured with functional magnetic resonance imaging. Measured at day 15 (after treatment period 1) and day 43 (after treatment period 2) (no baseline measures for fMRI).

Secondary outcome measures

1. Psychometric testing with standardised questionnaires (Wisconsin Card Sorting test, emotional stroop test, Beck Depression Inventory [BDI], Social Adaptation Self-evaluation Scale [SASS], Cognitive Dissonance Test [DISS], Befindlichkeits Skala [Mood Scale, BF-S], Beschwerden Liste [Complaint List, B-L], Eigenschaftswörterliste [Adjective Checklist, EWL-60], 36-item short form health survey [SF-36], Quality of Life Enjoyment and Satisfaction Questionnaire [QLES-Q])
2. Safety and tolerability

Measured at day 1, day 15, day 29 and day 43.

Overall study start date

01/03/2010

Completion date

31/10/2010

Eligibility

Key inclusion criteria

1. Aged 20 - 30 years
2. Male
3. Caucasian
4. Informed consent in accordance with the legal requirements
5. Healthy
6. Normal body weight

Participant type(s)

Patient

Age group

Adult

Sex

Male

Target number of participants

2 x 24 (48 in total)

Key exclusion criteria

1. Subjects with conspicuous findings in medical history and pre-study examination
2. Blood donation of approximately 500 ml within 3 months prior to the study start
3. A history of relevant diseases of vital organs, of the central nervous system or other organs
4. Subjects with a medical disorder, condition or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator or the sponsor
5. Febrile illness within 1 week before the start of the study
6. Subjects with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies
7. Regular daily consumption of more than 10 cigarettes
8. Regular daily consumption of more than half a litre of usual beer or the equivalent quantity of approximately 20 g of alcohol in another form
9. Regular use of therapeutic or recreational drugs
10. Use of medication within the 2 weeks preceding the study which could interfere with the investigational product
11. Relevant deviation from the normal range in the clinical examination
12. Relevant deviation from the normal range in clinical chemistry, haematology or urinalysis
13. Resting heart rate in the awake subject below 45 beats per minute (BPM) or above 90 BPM
14. Systolic blood pressure below 100 mmHg or above 140 mmHg
15. Diastolic blood pressure above 85 mmHg
16. Subjects testing positive in the drug screening
17. Excluded therapies (e.g., physiotherapy, acupuncture, etc)
18. Gastrointestinal disorders with uncertain absorption of orally administered drugs
19. Volunteer in custody or submitted to an institution due to a judicial order
20. Contraindications for magnetic resonance imaging: metallic implants (including non-removable body piercing), large tattoos, medical or biostimulation implants such as pacemaker, claustrophobia, allergy to the contrast agent

Date of first enrolment

01/03/2010

Date of final enrolment

31/10/2010

Locations**Countries of recruitment**

Germany

Study participating centre

Eschenallee 3

Berlin

Germany

14050

Sponsor information

Organisation

Dr. Willmar Schwabe GmbH & Co. KG (Germany)

Sponsor details

Willmar-Schwabe-Straße 4

Karlsruhe

Germany

76227

Sponsor type

Industry

Website

<http://www.schwabe.de/schwabe/>

ROR

<https://ror.org/043rrkc78>

Funder(s)**Funder type**

Industry

Funder Name

Dr. Willmar Schwabe GmbH & Co. KG (Germany)

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration